10.07.2013 • NewsAstraZenecaCancer researchcancer

AstraZeneca Signs Up First Cambridge Partners In Cancer Research

British pharmaceutical company AstraZeneca has agreed its first research partnerships in Cambridge for cancer treatments ahead of its relocation to the university city by 2016.

The firm said it would work on three oncology projects with Cancer Research UK and the University of Cambridge's department of oncology at Addenbrooke's Hospital, located next to the site for its new research center and headquarters. The projects include using blood tests to monitor tumors instead of biopsies, potential drugs for prostate cancer, and new approaches for pancreatic cancer, which has a very poor prognosis and few treatments available, the company said on Tuesday. AstraZeneca's move to Cambridge is the centerpiece of $2.3 billion restructuring plan unveiled by new chief executive Pascal Soriot in March. It confirmed last month that it would be based at the Cambridge Biomedical Campus.

Susan Galbraith, head of AstraZeneca's Oncology Innovative Medicines Unit, said it was fitting that the first collaborations since announcing the move were in cancer because its Cambridge facility will become its largest center for oncology research.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.